Wall Street brokerages expect Gilead Sciences, Inc. (NASDAQ:GILD) to announce $1.61 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Gilead Sciences’ earnings. The lowest EPS estimate is $1.36 and the highest is $1.77. Gilead Sciences posted earnings per share of $2.23 during the same quarter last year, which would suggest a negative year over year growth rate of 27.8%. The firm is expected to report its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that Gilead Sciences will report full-year earnings of $6.41 per share for the current fiscal year, with EPS estimates ranging from $6.17 to $6.80. For the next year, analysts expect that the company will post earnings of $6.56 per share, with EPS estimates ranging from $5.75 to $7.42. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same quarter last year, the firm posted $2.70 earnings per share. The firm’s revenue was down 18.7% on a year-over-year basis.
A number of analysts recently commented on GILD shares. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Credit Suisse Group reaffirmed a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Thursday, December 7th. Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 27th. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 8th. Finally, Argus downgraded Gilead Sciences from a “buy” rating to a “hold” rating and increased their price objective for the stock from $73.25 to $73.77 in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences has a consensus rating of “Buy” and a consensus price target of $87.04.
In other news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.51, for a total transaction of $2,087,750.00. Following the completion of the transaction, the executive vice president now directly owns 62,738 shares in the company, valued at $5,239,250.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the transaction, the executive vice president now owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The disclosure for this sale can be found here. Insiders have sold 418,333 shares of company stock valued at $32,742,108 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in GILD. Welch Investments LLC purchased a new stake in shares of Gilead Sciences during the third quarter valued at $108,000. Wealthcare Advisory Partners LLC purchased a new stake in shares of Gilead Sciences during the third quarter valued at $133,000. Horan Capital Advisors LLC. purchased a new stake in shares of Gilead Sciences during the third quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Gilead Sciences during the second quarter valued at $147,000. Finally, Hanson & Doremus Investment Management boosted its position in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 1,613 shares during the last quarter. 75.71% of the stock is currently owned by institutional investors.
Shares of Gilead Sciences (GILD) traded down $0.85 during mid-day trading on Monday, reaching $80.70. The company had a trading volume of 7,330,855 shares, compared to its average volume of 10,140,000. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $89.54. The stock has a market capitalization of $105,390.00, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of -1.85 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.55 and a quick ratio of 3.48.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s dividend payout ratio (DPR) is presently 59.77%.
TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Gilead Sciences, Inc. (GILD) to Announce $1.61 Earnings Per Share” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/19/brokerages-anticipate-gilead-sciences-inc-gild-to-announce-1-61-earnings-per-share.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Get a free copy of the Zacks research report on Gilead Sciences (GILD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.